Agomab Secures US Patent for Fibrosis Drug Through 2041

Edgen Stock

·Mar 26 2026, 11:26

Share to

Share to

Copy link

Key Takeaways

Agomab Therapeutics has secured a critical U.S. patent for its lead drug candidate, AGMB-447, significantly strengthening its intellectual property position in the competitive market for Idiopathic Pulmonary Fibrosis (IPF) treatments. This milestone provides a long-term competitive advantage ahead of key clinical trial results expected later this year.

Patent Secured: Agomab received U.S. Patent No. 12,577,230 for the composition of matter of its investigational IPF drug, AGMB-447.
Long-Term Protection: The patent provides intellectual property protection in the United States through at least 2041, de-risking the asset for commercial development and potential partnerships.
Next Catalyst: The company now awaits data from the Idiopathic Pulmonary Fibrosis patient cohort of its Phase 1b study, which is expected before the end of 2026.

Agomab Locks Down IP Protection for AGMB-447 Until 2041

Agomab Therapeutics (Nasdaq: AGMB) announced on March 26, 2026, that it received U.S. Patent No. 12,577,230 from the United States Patent and Trademark Office. The grant covers the composition of matter for AGMB-447, an investigational drug for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease with high unmet medical need. This patent provides foundational intellectual property protection in the U.S. market that extends through at least 2041, excluding any potential patent term extensions.

AGMB-447 is an inhaled small molecule inhibitor designed to target ALK5, a key regulator of fibrosis, directly in the lungs. This localized approach aims to deliver therapeutic effects while minimizing systemic exposure and potential side effects. The new patent is a crucial step in building a global IP portfolio for the drug candidate.

Patent Solidifies Market Position Ahead of Phase 1b Data

Securing a composition of matter patent, the strongest form of IP protection, provides Agomab with a significant competitive moat. The move strengthens the company's position as it prepares for potential partnership discussions and commercialization in the highly competitive fibrosis treatment landscape. With its foundational U.S. intellectual property now secure, the company's focus shifts to its ongoing clinical development.

The issuance of this patent is a significant milestone that solidifies the foundational IP for AGMB-447 in the U.S.

— Tim Knotnerus, Chief Executive Officer, Agomab

The next major catalyst for the company will be the clinical results from the IPF patient cohort of its Phase 1b study, which are expected later this year. Positive data from this trial, combined with the long-term patent protection, would substantially enhance the value of AGMB-447 and bolster Agomab's position in developing new therapies for fibro-inflammatory diseases.